$TNXP News Article - Tonix Pharmaceuticals Announces 12-Week Primary Endpoint and Addition of Adaptive Design Features in the Currently-Enrolling Phase 3 RECOVERY Study of Tonmya for PTSD, Following FDA Meeting
https://marketwirenews.com/news-releases/toni...31751.html